Drug Trial Radar · NCT04719832
Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype
Last checked: Nov 20, 2026Latest source record: Dec 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
395
Actual
Start
Mar 17, 2021
Primary completion
Nov 21, 2023
Study completion Nov 21, 2023
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- IQVIA Pty Ltd
- First posted
- Jan 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, randomized, placebo-controlled, double-blind, parallel group study that aims to assess the efficacy and safety of GSK3511294 (Depemokimab) in participants with severe uncontrolled asthma with an eosinophilic phenotype
Conditions
- Asthma
Interventions
GSK3511294 (Depemokimab)Biological
GSK3511294 (Depemokimab) will be administered using a pre-filled syringe.
PlaceboDrug
Matching placebo will be administered as a normal saline using a pre-filled syringe.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Rate of Clinically Significant Exacerbations up to 52 WeeksTime frame: Up to Week 52
Locations
123 sites in 12 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Encinitas, California
GSK Investigational Site
Long Beach, California
GSK Investigational Site
Pasadena, California
GSK Investigational Site
Rancho Cucamonga, California
GSK Investigational Site
San Jose, California
GSK Investigational Site
Coral Gables, Florida
GSK Investigational Site
Loxahatchee Groves, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
New Port Richey, Florida
GSK Investigational Site
Orlando, Florida
GSK Investigational Site
Alpharetta, Georgia
GSK Investigational Site
Calhoun, Georgia
GSK Investigational Site
Columbus, Georgia
GSK Investigational Site
Savannah, Georgia
GSK Investigational Site
Normal, Illinois
GSK Investigational Site
Lexington, Kentucky
GSK Investigational Site
Owensboro, Kentucky
GSK Investigational Site
Rochester Hills, Michigan
GSK Investigational Site
Las Vegas, Nevada
GSK Investigational Site
New York, New York
GSK Investigational Site
The Bronx, New York
GSK Investigational Site
Gastonia, North Carolina
GSK Investigational Site
Cleveland, Ohio
GSK Investigational Site
Boerne, Texas
GSK Investigational Site
Cypress, Texas
GSK Investigational Site
Cypress, Texas
GSK Investigational Site
Dallas, Texas
GSK Investigational Site
Kerrville, Texas
GSK Investigational Site
San Antonio, Texas
GSK Investigational Site
Ajax, Ontario, Canada
GSK Investigational Site
Niagara Falls, Ontario, Canada
GSK Investigational Site
Ottawa, Ontario, Canada
GSK Investigational Site
Windsor, Ontario, Canada
GSK Investigational Site
Québec, Quebec, Canada
GSK Investigational Site
Changchun, China
GSK Investigational Site
Changchun, China
GSK Investigational Site
Changsha, China
GSK Investigational Site
Chengdu, China
GSK Investigational Site
Guangzhou, China
Showing 40 of 123 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.